Fiche traitement
GnRH, gonadorelin acetate
Nelly Pitteloud • Alzheimer
Suivi actif
Phase 2
Résumé
GnRH, gonadorelin acetate est développé par Nelly Pitteloud. Le traitement est actuellement en Phase 2. Il est associé à Alzheimer. Son objectif thérapeutique principal est Immunomodulation. Le statut actuel est : suivi actif.
À vérifier
Immunomodulation
Phase 2
Nelly Pitteloud
Switzerland
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old. Early Alzheimer's disease (AD) is the most common cause of death within this population. DS individuals already show AD neuropathology by the age of 30, while it becomes clinically recognized in their late forties. DS subjects also exhibit olfaction defects in adulthood.
To date, there is no treatment available for the cognitive or olfactory defects in DS. The development of an effective treatment targeting cognitive dysfunction in DS adolescents/adults would be warranted.
GnRH, a decapeptide secreted by hypothalamic neurons is the pilot light of reproduction in all mammals. Pulsatile GnRH acts on the gonadotrophs via the GnRH receptor (GNRHR) in the pituitary gland to stimulate LH and FSH, which themselves will act on the gonads to produce gametes and steroids. However, GNRHR are also expressed in cerebral cortex, hippocampus, amygdala, habenula, olfactory structures, and adrenal gland, suggesting that GnRH may have a role beyond reproduction.
Recently, GnRH has been shown to be involved in the process of ageing and lifespan control. Notably, in murine models, GnRH acts as an anti-ageing factor, independent of sex hormones. While ageing is characterized by hypothalamic inflammation and diminished neurogenesis, particularly in the hypothalamus and the hippocampus, GnRH was able to promote adult neurogenesis.
The regulation of GnRH secretion is complex and involves hormonal, neuronal input, and environmental factors.
Prévot et al. recently explored cognition within the Ts65Dn model and showed an age-dependent loss of the ability to recognize new objects. Also, these mice exhibit defects in olfaction. Given the role of GnRH in anti-aging mice model, pulsatile GnRH or continuous GnRH infusion (leading to desensitization of the GNRHR) were given to the Ts65Dn mice for two weeks. Amazingly, pulsatile but not continuous GnRH therapy was able to recover cognitive and olfaction defects.
2024-02-09
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 2
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Immunomodulation
Confiance automatique : 66%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : inflamm → Immunomodulation
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT04390646, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Aucune incohérence majeure détectée entre la maladie, l’objectif et la description.
Transparence et qualité de la fiche
données vérifiablesClassificationCohérente automatiquement
Confiance de la fiche100 %
Source principaleSource officielle ou publication indexée
Dernière vérification2024-02-09
Anomalies détectées0
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 2
Études associées1
Publications associées17
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
22 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2020-08-27 | Début de l’étudeNCT04390646 | Registre d’essai clinique |
| 2024-02-09 | Dernière mise à jour des donnéesGnRH, gonadorelin acetate | Biomedical Watch |
| 2026-07-08 | Création de l’enregistrementNCT04390646 | Registre d’essai clinique |
| 2026-07-08 | PublicationSingle-nuclei RNA sequencing reveals heterogeneity within developing GnRH3 neurons in zebrafish. | Journal of neuroendocrinology |
| 2026-07-08 | PublicationA survey on treatment satisfaction with leuprorelin acetate in girls with central precocious puberty. | Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology |
| 2026-07-10 | PublicationObesity Alters the Estrogen-Induced Luteinizing Hormone Surge in Ovariectomized Ewes. | Biology of reproduction |
| 2026-07-12 | PublicationGamma-aminobutyric acid supplementation combined with gonadotropin-releasing hormone analog therapy versus gonadotropin-releasing hormone analog therapy alone for linear growth in children with growth retardation: a retrospective cohort study. | Translational pediatrics |
| 2026-07-12 | PublicationClinical features and reproductive outcomes after first frozen embryo transfer in patients with different ultrasound-diagnosed adenomyosis subtypes following ultralong gonadotropin-releasing hormone agonist pretreatment: a retrospective cohort study. | BMC pregnancy and childbirth |
| 2026-07-13 | Dernière mise à jour du registreNCT04390646 | Registre d’essai clinique |
| 2026-07-14 | PublicationCell-free MSC secretome therapy ameliorates diabetic testicular injury via antioxidant mechanisms. | Journal of molecular histology |
| 2026-07-14 | PublicationDiagnostic utility of basal luteinizing hormone in evaluating central precocious puberty. | Journal of the Endocrine Society |
| 2026-07-14 | PublicationOutcomes of GnRH Agonist Therapy in Boys with Central Precocious Puberty: A Systematic Review of Final Height and Long-Term Health Effects. | International journal of preventive medicine |
| 2026-07-18 | PublicationIncidence study of precocious puberty in the population of the state of Goiás: did the COVID-19 pandemic modify the epidemiology? | Jornal de pediatria |
| 2026-07-18 | PublicationPulmonary alveolar proteinosis diagnosed during leuprorelin acetate therapy for ovarian endometrioma: a case report. | BMC pulmonary medicine |
| 2026-07-22 | PublicationRegulation of ovarian function in domestic animals: translational insights into human ovarian dynamics and dysfunction. | Frontiers in endocrinology |
| 2026-07-22 | PublicationOptimizing ovulation synchronization in Holstein heifers: implementing a half-dose GnRH analogue (Buserelin Acetate) in a nanofabricated form within the ovsynch protocol to enhance the ovarian activity and reproductive performance outcomes. | Frontiers in veterinary science |
| 2026-08-08 | PublicationThe diagnostic value and optimal cutoff of basal luteinizing hormone for central precocious puberty in premenarcheal girls stratified by weight status. | Frontiers in endocrinology |
| 2026-08-08 | PublicationEffects of extending interval between presynchronization and breeding protocols and prostaglandin F2α administration before breeding protocol on reproductive performance of Holstein dairy cows during summer. | Veterinary and animal science |
| 2026-08-13 | PublicationInvestigation of Adverse Events Associated with Predicted GnRHR Agonists Using the FAERS Database. | International journal of molecular sciences |
| 2026-08-16 | PublicationProtocol flexibility in PCOS: a combination of controlled ovarian stimulation and endometrial preparation strategies shows no impact on live birth outcomes after frozen embryo transfer-a retrospective cohort study. | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology |
| 2026-08-16 | PublicationRelugolix combination therapy in symptomatic adenomyosis and uterine fibroids: a case series. | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology |
| 2028-12-01 | Fin de l’étude prévue / enregistréeNCT04390646 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT04390646 | GnRH Therapy on Cognition in Down Syndrome | Phase 2 | RECRUITING | Switzerland | Nelly Pitteloud |
Publications liées
17 publication(s)Publications liées
17 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Protocol flexibility in PCOS: a combination of controlled ovarian stimulation and endometrial preparation strategies shows no impact on live birth outcomes after frozen embryo transfer-a retrospective cohort study. Voir source | 41934169 | 10.1080/09513590.2026.2650027 | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology | |
| Relugolix combination therapy in symptomatic adenomyosis and uterine fibroids: a case series. Voir source | 41999195 | 10.1080/09513590.2026.2659439 | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology | |
| Investigation of Adverse Events Associated with Predicted GnRHR Agonists Using the FAERS Database. Voir source | 42589332 | 10.3390/ijms27156675 | International journal of molecular sciences | |
| The diagnostic value and optimal cutoff of basal luteinizing hormone for central precocious puberty in premenarcheal girls stratified by weight status. Voir source | 42564140 | 10.3389/fendo.2026.1900964 | Frontiers in endocrinology | |
| Effects of extending interval between presynchronization and breeding protocols and prostaglandin F2α administration before breeding protocol on reproductive performance of Holstein dairy cows during summer. Voir source | 42564643 | 10.1016/j.vas.2026.100780 | Veterinary and animal science | |
| Regulation of ovarian function in domestic animals: translational insights into human ovarian dynamics and dysfunction. Voir source | 42483683 | 10.3389/fendo.2026.1863960 | Frontiers in endocrinology | |
| Optimizing ovulation synchronization in Holstein heifers: implementing a half-dose GnRH analogue (Buserelin Acetate) in a nanofabricated form within the ovsynch protocol to enhance the ovarian activity and reproductive performance outcomes. Voir source | 42483712 | 10.3389/fvets.2026.1874230 | Frontiers in veterinary science | |
| Incidence study of precocious puberty in the population of the state of Goiás: did the COVID-19 pandemic modify the epidemiology? Voir source | 42468908 | 10.1016/j.jped.2026.101590 | Jornal de pediatria | |
| Pulmonary alveolar proteinosis diagnosed during leuprorelin acetate therapy for ovarian endometrioma: a case report. Voir source | 42469731 | 10.1186/s12890-026-04507-5 | BMC pulmonary medicine | |
| Cell-free MSC secretome therapy ameliorates diabetic testicular injury via antioxidant mechanisms. Voir source | 42446804 | 10.1007/s10735-026-10896-y | Journal of molecular histology | |
| Diagnostic utility of basal luteinizing hormone in evaluating central precocious puberty. Voir source | 42440719 | 10.1210/jendso/bvag131 | Journal of the Endocrine Society | |
| Outcomes of GnRH Agonist Therapy in Boys with Central Precocious Puberty: A Systematic Review of Final Height and Long-Term Health Effects. Voir source | 42441186 | 10.4103/ijpvm.ijpvm_120_25 | International journal of preventive medicine | |
| Gamma-aminobutyric acid supplementation combined with gonadotropin-releasing hormone analog therapy versus gonadotropin-releasing hormone analog therapy alone for linear growth in children with growth retardation: a retrospective cohort study. Voir source | 42433946 | 10.21037/tp-2026-1-0024 | Translational pediatrics | |
| Clinical features and reproductive outcomes after first frozen embryo transfer in patients with different ultrasound-diagnosed adenomyosis subtypes following ultralong gonadotropin-releasing hormone agonist pretreatment: a retrospective cohort study. Voir source | 42436422 | 10.1186/s12884-026-09624-x | BMC pregnancy and childbirth | |
| Obesity Alters the Estrogen-Induced Luteinizing Hormone Surge in Ovariectomized Ewes. Voir source | 42421243 | 10.1093/biolre/ioag135 | Biology of reproduction | |
| Single-nuclei RNA sequencing reveals heterogeneity within developing GnRH3 neurons in zebrafish. Voir source | 42415515 | 10.1111/jne.70230 | Journal of neuroendocrinology | |
| A survey on treatment satisfaction with leuprorelin acetate in girls with central precocious puberty. Voir source | 42415823 | 10.1297/cpe.2025-0112 | Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology |
Sources officielles
liens de rechercheDernière mise à jour des données : 2024-02-09
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.